Evidence map›Paper›PMID 34390490›Full record

SynthesisEuropean journal of clinical investigation2021

Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications.

Giacomo Tini, Eugenio Sessarego, Stefano Benenati, Pier Filippo Vianello, Beatrice Musumeci, Camillo Autore, Marco Canepa

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Giacomo TiniCardiology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Eugenio SessaregoCardiology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Stefano BenenatiCardiology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Pier Filippo VianelloCardiology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Beatrice MusumeciDivision of Cardiology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
Camillo AutoreDivision of Cardiology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
Marco CanepaCardiology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.ORCID https://orcid.org/0000-0001-9063-5576
University of Genoa · ITSapienza University of Rome · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransthyretin-related cardiac amyloidosis (TTR-CA) is thought to be particularly common in specific at-risk conditions, including aortic stenosis (AS), heart failure with preserved ejection fraction (HFpEF), carpal tunnel syndrome (CTS) and left ventricular hypertrophy or hypertrophic cardiomyopathy (LVH/HCM).

methodsWe performed a systematic revision of the literature, including only prospective studies performing TTR-CA screening with bone scintigraphy in the above-mentioned conditions. Assessment of other forms of CA was also evaluated. For selected items, pooled estimates of proportions or means were obtained using a meta-analytic approach.

resultsNine studies (3 AS, 2 HFpEF, 2 CTS and 2 LVH/HCM) accounting for 1375 screened patients were included. One hundred fifty-six (11.3%) TTR-CA patients were identified (11.4% in AS, 14.8% in HFpEF, 2.6% in CTS and 12.9% in LVH/HCM). Exclusion of other forms of CA and use of genetic testing was overall puzzled. Age at TTR-CA recognition was significantly older than that of the overall screened population in AS (86 vs. 83 years, p = .04), LVH/HCM (75 vs. 63, p < .01) and CTS (82 vs. 71), but not in HFpEF (83 vs. 79, p = .35). In terms of comorbidities, hypertension, diabetes and atrial fibrillation were highly prevalent in TTR-CA-diagnosed patients, as well as in those with an implanted pacemaker.

conclusionsScreening with bone scintigraphy found an 11-15% TTR-CA prevalence in patients with AS, HFpEF and LVH/HCM. AS and HFpEF patients were typically older than 80 years at TTR-CA diagnosis and frequently accompanied by comorbidities. Several studies showed limitations in the application of recommended TTR-CA diagnostic algorithm, which should be addressed in future prospective studies.

Indexed as

Amyloid Neuropathies, FamilialAmyloidosisAortic Valve StenosisCardiomyopathiesCardiomyopathy, HypertrophicCarpal Tunnel SyndromeHeart FailureHumansHypertrophy, Left VentricularRadionuclide ImagingStroke Volumeaortic stenosiscarpal tunnel syndromeheart failureleft ventricular hypertrophytransthyretin cardiac amyloidosis

Identifiers

PMID34390490
PMCPMC9286629
OpenAlexW3189185844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.